Pharm MT 1 Part IV

Submit

2. Use of actual body weight in obese patients may significanly _______ CrCl.

In obese patients, need to use adujusted body weight (ABW) instead when calculating CrCl and doses.

pg. 26

Explanation

In obese patients, need to use adujusted body weight (ABW) instead when calculating CrCl and doses.

pg. 26

Submit

4. How strongly a drug molecule binds to a binding site is referred to as:

Binding strength

Affiliation

Affinity

Affixation

pg. 28

The dissociation constant (K sub D) describes the degree of a drug's affinity for the receptor site. This is the concentration of drug in solution necessary for 50% of given receptors to be occupied (pg. 29)

Explanation

pg. 28

The dissociation constant (K sub D) describes the degree of a drug's affinity for the receptor site. This is the concentration of drug in solution necessary for 50% of given receptors to be occupied (pg. 29)

5. What drug info monograph section should an OD review in order to find info on how the drug actually works?

Indications

Mechanism of action

Pharmakodynamics

Dosage

question from lecture

Explanation

question from lecture

6. ________ is a concept often used when comparing the effects in the same class of drugs.

Irreversible antagonism

Drug efficiency

Drug efficacy

Drug potency

-vs-
Drug efficacy: used when comparing the effects od drugs in DIFFERENT classes or which have different mechs of

pg. 29

Explanation

-vs-
Drug efficacy: used when comparing the effects od drugs in DIFFERENT classes or which have different mechs of

pg. 29

7. Which of the drug monograph sections should an OD review o find info on the half life, onset of action, binding mechanism and elimination?

Indications

Mech of action

Pharmacokinetics/dynamics

Administration

question from lecture

Explanation

question from lecture

8. The creatinine clearance of a female is what percent of a males?

55%

65%

75%

85%

pg.26

Explanation

pg.26

9. High doses of agnosits can overcome competitive antagonism.

True

False

Competitive antagonism: antagonist competes with agonists for receptor site

pg. 29

Explanation

Competitive antagonism: antagonist competes with agonists for receptor site

pg. 29

10. High doses of agonists can overcome non-competitive antagonism.

True

False

non-competitive antagonism: antagonist binds to sites OTHER THAN the agonist-binding domain

pg. 29

Explanation

non-competitive antagonism: antagonist binds to sites OTHER THAN the agonist-binding domain

pg. 29

11. Renal dose adjustments are not usually needed unless the CrCl is less than ____mL/min.

10

25

50

65

Some drugs do not need to be adjusted until the clearance is lower..

pg. 27

Explanation

Some drugs do not need to be adjusted until the clearance is lower..

pg. 27

12. DNA transcription, steroid production, stimulation of red blood production are all examples of what type of event in response to drug binding to receptor sites?

Activation of cellular function

Inhibition of cellular function

Activation of biochemical processes

Opening or closing of ionic channels

pg. 28

Explanation

pg. 28

13. The margin between the therapeutic dose and the lethal dose of a drug is termed _____.

Therapeutic index

Lethal index

Margin of safety

Margin of death

pg. 30

Explanation

pg. 30

14. Which of the following is NOT involved in the hepatobiliary excretion process?

Liver

Bile

Gall bladder

None of the above (all are involved)

liver --> gall bladder --> bile --> feces

pg. 26

Explanation

liver --> gall bladder --> bile --> feces

pg. 26

15. What category for Pregnancy Risk Factors is a contra-indication in women who are or may become pregnant?

A

C

D

X

Both options C and D

pg. 37

Explanation

pg. 37

16. Where do agonists bind?

Intracellular receptors

Plasma membranes

Nuclear membranes

All of the above

More than one of the above

agonists are drugs which change or affect cellular physiology by binding to INTRACELLULAR RECEPTORS or PLASMA MEMBRANES

(pg. 29)

Explanation

agonists are drugs which change or affect cellular physiology by binding to INTRACELLULAR RECEPTORS or PLASMA MEMBRANES

(pg. 29)

17. What Pregnancy Risk Factor Category corresponds to a drug that has no animal or female studies available to determine risks.

A

B

C

D

X

pg. 37

Explanation

pg. 37

Pharm Mt 1 Part IV

1. The SCr is a _____ sensitive indicator of renal function than the BUN.

2.

What first name or nickname would you like us to use?

2. Use of actual body weight in obese patients may significanly _______ CrCl.

3. The amount of drug required to produce 50% of the maximal response that the drug is capable of inducing is the definition for ___________.

4. How strongly a drug molecule binds to a binding site is referred to as:

5. What drug info monograph section should an OD review in order to find info on how the drug actually works?

6. ________ is a concept often used when comparing the effects in the same class of drugs.

7. Which of the drug monograph sections should an OD review o find info on the half life, onset of action, binding mechanism and elimination?

8. The creatinine clearance of a female is what percent of a males?

9. High doses of agnosits can overcome competitive antagonism.

10. High doses of agonists can overcome non-competitive antagonism.

11. Renal dose adjustments are not usually needed unless the CrCl is less than ____mL/min.

12. DNA transcription, steroid production, stimulation of red blood production are all examples of what type of event in response to drug binding to receptor sites?

13. The margin between the therapeutic dose and the lethal dose of a drug is termed _____.

14. Which of the following is NOT involved in the hepatobiliary excretion process?

15. What category for Pregnancy Risk Factors is a contra-indication in women who are or may become pregnant?

16. Where do agonists bind?

17. What Pregnancy Risk Factor Category corresponds to a drug that has no animal or female studies available to determine risks.